Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Axcan Pharma has launched its inflammatory bowel disease treatment Canasa 1,000mg, the only FDA approved once-daily mesalamine suppository for the treatment of ulcerative proctitis, in the US.
Subscribe to our email newsletter
Axcan received a three-year marketing exclusivity for the new dosage form under the non-patent exclusivity provisions of the Federal Food, Drug and Cosmetic Act.
“The once-a-day Canasa 1,000mg suppository offers a new treatment option for patients with ulcerative proctitis,” said Dr Miguel Regueiro, associate professor of medicine and co-director of the Inflammatory Bowel Disease Center at the University of Pittsburgh Medical Center.
“The 1,000mg suppository is as efficacious as the twice-a-day Canasa 500mg suppository, but 1,000 mg once a day is easier for patients to use and should improve compliance.”
In the US, the rectal mesalamine market is valued at approximately $82 million annually and it is currently estimated that there are approximately one million cases of inflammatory bowel disease in the US, with around 400,000 new cases every year.